Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

A South Korean study explored the link between lifestyle decisions beginning in infancy and persistent atopic dermatitis, ...

Sana Biotechnology’s hypoimmune platform enables it to make a series of genetic modifications to cells, rendering the cells ...

The healthcare industry can’t afford to be stagnant. Cost pressures, operational pressures and real human lives are at stake ...

The Federal Trade Commission suggests that PBMs profit from specialty generic drugs such as those for cancer and HIV and ...

In 2025, AI [artificial intelligence] will play a larger role in driving payer operational improvements and offer health insurers a more comprehensive view of member health.

The antibody-drug conjugate (ADC), marketed by ADC Therapeutics under the brand name Zynlonta, received accelerated approval ...

If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A prediction for 2025 by Marci Chodroff, M.D., vice president of Medical Affairs at Prime Therapeutics and Managed Healthcare ...

Study authors Susan D. Reed, MD, MPH, MS, and Erin Dwyer, MPH, both at the University of Washington School of Medicine, attribute some of these different challenges to underlying health disparities.

Kimberly Westrich, M.A., chief strategy officer of National Pharmaceutical Council, shares her prediction for 2025.

Employer purchasers have largely been on the sidelines when it comes to policy proposals that target high healthcare prices.